Deutetrabenazine ($ Austedo)
VMAT2 inhibitor (reduces dopamine release)
- Tardive dyskinesia
Features
Dosing
6mg 1 bid x7days, 9mg 1 bid x7days, 12mg 1 bid x7days, 15mg 1 bid x7days, 18mg 1 bid x7days, 21mg 1 bid x7days, then 24mg 1 bid (or dose by response). Take with food.
Management
Second line to valbenazine (as deutetrabenazine has smaller effect, BID dosing, food interaction).
If does not work or cannot afford, consider amantadine, levetiracetam, or ginkgo for TD.
RISK: QTC prolongation
EMR Text
Tardive dyskinesia
Deutetrabenazine use based on FDA approval in tardive dyskinesia.
Deutetrabenazine side effects, including cardiac (QTc), reviewed with patient.